logo
Plus   Neg
Share
Email

Regeneron To Invest $800 Mln In Alnylam; To Jointly Develop RNAi Therapeutics

Regeneron Pharmaceuticals, Inc. (REGN) and Alnylam Pharmaceuticals, Inc. (ALNY) announced a collaboration to discover, develop and commercialize new RNA interference therapeutics focused on ocular and Central Nervous System (CNS) diseases. Regeneron will lead development and commercialization for all programs targeting eye diseases, with Alnylam entitled to potential milestone and royalty payments. The companies plan to advance programs directed to 30 targets and introduce many into clinical development during the initial five-year discovery period, which includes an option to extend.

Regeneron has agreed to make a $400 million upfront payment to Alnylam and to purchase $400 million of Alnylam equity at a price per share of $90.00 (4.44 million common shares). Alnylam is eligible to receive up to an additional $200 million in milestone payments upon achievement of certain criteria during early clinical development for the eye and CNS programs.

The collaboration will build on Alnylam's recent preclinical data showing potent delivery of RNAi therapeutics to achieve target gene silencing in the eye and CNS. The collaboration also includes a select number of RNAi therapeutic programs designed to target genes expressed in the liver, which can influence a wide variety of diseases throughout the body.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Kader Exports pvt. Ltd. is recalling certain consignments of various frozen cooked shrimp citing potential contamination with Salmonella, according to the U.S. Food and Drug Administration. The affected frozen cooked, peeled and deveined shrimp products were sold in 1lb, 1.5lb., and 2lb. retail bags. They were distributed from late February 2020 to Mid-May 2020 across the nation. The former chief executive officer of Hertz Global Holdings, Mark Frissora, agreed to pay about $2.2 million to settle the U.S. Securities and Exchange Commission's claims that he played a key role in causing the now-bankrupt car-rental company to file inaccurate financial statements in 2013. Daimler AG, the maker of Mercedes-Benz cars, said Thursday that it has agreed to pay more than $2.2 billion to settle U.S. claims over emissions from its diesel vehicles.
Follow RTT